Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

Shopping News / Articles


bioengineer.org > faster-amyloidosis-typing-with-high-flow-mass-spectrometry-reaches-the-clinic

Faster Amyloidosis Typing with High-Flow Mass Spectrometry Reaches the

1+ day, 22+ hour ago   (573+ words) For patients with amyloidosis, the difference between receiving the right treatment and the wrong one can hinge on a deceptively simple question: which protein is actually forming the deposits? Amyloidosis is not one disease but a family of disorders in…...


tradingview.com > news > urn:summary_document_transcript:quartr.com:4152011:0-pmn-interim-trial-data-show-favorable-safety-and-promising-biomarker-results-for-a-new-alzheimer-s-antibody

PMN: Interim trial data show favorable safety and promising biomarker results for a new Alzheimer's antibody

3+ day, 22+ hour ago   (81+ words) TradingView PMN: Interim trial data show favorable safety and promising biomarker results for a new Alzheimer's antibody A novel antibody therapy for Alzheimer's showed zero cases of brain swelling and strong biomarker engagement in a robust phase I-B trial, with…...


tradingview.com > news > urn:summary_document_transcript:quartr.com:4150789:0-abos-phase-ii-trial-of-sabirnetug-targets-toxic-oligomers-in-alzheimer-s-with-pivotal-data-due-late-2026

ABOS: Phase II trial of sabirnetug targets toxic oligomers in Alzheimer's, with pivotal data due late 2026

4+ day, 3+ hour ago   (87+ words) TradingView ABOS: Phase II trial of sabirnetug targets toxic oligomers in Alzheimer's, with pivotal data due late 2026 The conference highlighted a rapidly growing Alzheimer's market and detailed the phase II ALTITUDE-AD trial of sabirnetug, targeting toxic A-beta oligomers with data…...


tradingview.com > news > urn:summary_document_transcript:quartr.com:4146077:0-abos-phase-ii-data-for-a-novel-alzheimer-s-antibody-is-expected-in-late-2024-with-ebd-ind-in-2027

ABOS: Phase II data for a novel Alzheimer's antibody is expected in late 2024, with EBD IND in 2027

4+ day, 19+ hour ago   (87+ words) TradingView Sabirnetug, a highly selective A-beta oligomer antibody, is in phase II for early Alzheimer's, with data expected late 2024. The Enhanced Brain Delivery program, leveraging JCR's technology, targets an IND in mid-2027, with two candidates in development. ALTITUDE results will validate…...


eurekalert.org > news-releases > 1143356

New research offers avenue to explore relationship between Alzheimer’s, HIV

4+ day, 20+ hour ago   (547+ words) Animal model may provide key for development of novel therapeutics image: From left, Pravin Yeapuri, PhD, Howard Gendelman, MD, and Shaurav Bhattarai, PhD view more Credit: University of Nebraska Medical Center UNMC researchers have published an article in Alzheimer’s & Dementia:…...


wsbt.com > news > local > alzheimers-research-developments-treatments-cause-protein-buildup-factors-plaques-tangles-slow-disease-progression-decrease-symptoms-relief-psychology-professor-notre-dame-south-bend-indiana

Alzheimer's research leads to new treatments

5+ day, 2+ hour ago   (360+ words) by Liliana Herrera, WSBT 22 Reporter SOUTH BEND, Ind. (WSBT) — September is Alzheimer's Awareness Month — a time to raise awareness about a disease affecting millions of people and the families who care for them. But researchers are learning more about what…...


cityandstateny.com > politics > 2026 > 09 > rahm-emanuel-still-talking-about-his-meeting-zohran-mamdani > 415861

Rahm Emanuel is still talking about his meeting with Zohran Mamdani

5+ day, 8+ hour ago   (376+ words) Former Chicago Mayor Rahm Emanuel hits the campaign trail for a congressional candidate in New Jersey. John Celock “That was a long no. We talked. I said, this is, are we doing an interview, or (are) we trying to recap?...


quiverquant.com > news > Cognition+Therapeutics+to+Present+Zervimesine+Development+Progress+at+H.C.+Wainwright+Global+Investment+Conference

Cognition Therapeutics to Present Zervimesine Development Progress at H.C. Wainwright Global Investment Conference | CGTX Stock News

6+ day, 5+ hour ago   (212+ words) 50% off your first year of any Quiver subscription Lisa Ricciardi will present on September 15, 2026, at the H.C. Wainwright 28th Annual Global Investment Conference at 2:30 p.m. ET. Ms. Ricciardi will discuss progress on the development of zervimesine for Alzheimer's disease and dementia with Lewy…...


nashaniva.com > en > 404041

Two injections — and the end of Alzheimer's disease? It worked in mice

6+ day, 16+ hour ago   (346+ words) Astrocytes are interesting because during embryonic development they can themselves transform into neurons. However, in an adult organism, this ability is blocked. One of the key factors that prevents such transformation is considered to be the PTBP1 protein. A team of…...


crossriverwatch.com > 2026 > 09 > south-south-governors-move-to-build-regional-economic-powerhouse

South-South Governors Move To Build Regional Economic Powerhouse

6+ day, 9+ hour ago   (483+ words) The resolution formed the thrust of the communiqué issued at the end of the second meeting of the South-South Governors’ Forum, held in Calabar, Cross River State, on Monday September 7, 2026, under the chairmanship of Bayelsa State Governor, Senator Douye Diri....

Shopping

Please enter a search for detailed shopping results.